MO42-6 The clinical and molecular landscape of focal MET-amplified metastatic colorectal cancer patients

MET amplification (amp) is rare in untreated metastatic colorectal cancer (mCRC), but cell-free DNA (cfDNA) analysis identifies it in 20% with anti-EGFR monoclonal antibody (mAb) refractory disease. We previously reported that cfDNA could detect focal versus non-focal MET amp in mCRC, and focal MET amp may be a better predictor of benefit from a MET inhibitor (Ann Oncol.2019; 30(suppl_5): abstr3022). However, the clinical and molecular landscape of MET amp mCRC is not well understood.